Status:
COMPLETED
Eletriptan Provides Consistent Migraine Relief: Results Of A Within-Patient Multiple-Dose Study
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Migraine Without Aura
Migraine With Aura
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
Evaluation of headache response at 2 hours for active treated attacks for increasing dose.
Eligibility Criteria
Inclusion
- Male and Female subjects in good general health, aged 18 to 65 years.
- Subjects should meet IHS diagnostic criteria for migraine with or without aura.
- Based on past history, subjects should expect to suffer at least one acute attack of migraine with or without aura, each 6 weeks
Exclusion
- Known coronary-artery disease, clinically significant arrhythmia, heart failure, or uncontrolled hypertension.
- Pregnant or lactating women.
- Clinically significant electrocardiogram abnormalities at screening.
Key Trial Info
Start Date :
March 1 2000
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2002
Estimated Enrollment :
971 Patients enrolled
Trial Details
Trial ID
NCT01859481
Start Date
March 1 2000
End Date
March 1 2002
Last Update
January 27 2021
Active Locations (148)
Enter a location and click search to find clinical trials sorted by distance.
1
Eeuwfeestkliniek
Antwerp, Belgium, 2018
2
A.Z. Sint Jan
Bruges, Belgium, 8000
3
Cliniques Universitaires St Luc
Brussels, Belgium, 1200
4
C.H.U. de Charleroi
Charleroi, Belgium, 6000